High Tide Inc.

High Tide Inc. announced preliminary guidance for its third fiscal quarter ended July 31, 2026, projecting record revenue, gross profit, and Adjusted EBITDA. The company expects revenue between C$195.0 million and C$200.0 million, gross profit between C$51.0 million and C$53.5 million, and Adjusted EBITDA between C$15.2 million and C$16.5 million, all exceeding analyst forecasts. Additionally, its German subsidiary, Remexian Pharma GmbH, achieved a record quarterly distribution of over 10 tonnes of medical cannabis.

High Tide Inc. announced the opening of a new Canna Cabana retail cannabis store in Ottawa, Ontario, expected to commence sales on July 24, 2026. This expansion brings the company's total Canna Cabana locations to 229 across Canada and 104 in Ontario. The new store is strategically located in Findlay's Creek, a rapidly growing suburb, aiming to strengthen High Tide's presence in the region and leverage its membership programs.

High Tide Inc. CEO Raj Grover held his fifth Reddit Ask Me Anything (AMA) session on July 15, 2026, engaging directly with shareholders on the company's strategy, operations, and outlook. This session follows an active period for the company, including the release of its second quarter fiscal 2026 financial results, the announced acquisition of Northern Helm, approval of C$40 million in new senior credit facilities, and continued expansion of its international medical cannabis business in Germany.

High Tide Inc. has amended and restated its Shareholder Rights Plan Agreement, originally established on April 10, 2025. The updated plan, confirmed by independent shareholders on August 11, 2026, aims to ensure fair treatment of shareholders during takeover bids and to help the company maintain compliance with Cannabis Laws and Licenses. It defines an "Acquiring Person" as someone beneficially owning 20% or more of voting shares, or meeting specific criteria related to cannabis licensing regulations in Ontario and British Columbia that could jeopardize High Tide's licenses.

High Tide Inc. announced its Annual General and Special Meeting of Shareholders will be held virtually on August 11, 2026, with a record date of June 29, 2026. Shareholders will vote on key corporate governance matters, including the reappointment of Davidson & Company LLP as auditor, fixing the number of directors at five, and the election of directors. Additionally, the meeting will address the ratification and approval of an amended and restated shareholder rights plan, which includes updates to the definition of an "Acquiring Person" concerning cannabis retail licenses.

High Tide Inc. announced the adoption of a Temporary Shareholder Rights Plan and an Amended and Restated Shareholder Rights Plan. These plans are designed to ensure the company's compliance with cannabis laws, maintain its licenses, and ensure fair treatment of shareholders during any acquisition offers. The key amendments expand the definition of "Acquiring Person" to include certain cannabis retail license holders in Ontario and British Columbia to prevent non-compliance with provincial regulations. The Temporary plan serves as an interim measure until shareholders ratify the Amended and Restated plan at the upcoming meeting on August 11, 2026.

High Tide Inc.'s German subsidiary, Remexian Pharma GmbH, showcased its exclusive Canadian medical cannabis brand partnerships at Mary Jane Berlin 2026. Remexian is bringing premium Canadian medical cannabis products from brands like Tribal and Highly Dutch Organic to German patients and pharmacies, strengthening its position as a leading importer and distributor in Germany's rapidly growing medical cannabis market. This initiative supports Remexian's continued expansion of its pharmacy network and reinforces High Tide's strategy to build a globally diversified cannabis platform.

High Tide Inc. announced its second quarter 2026 financial results, featuring record revenue of $179.3 million, a 30% increase year-over-year, and record Adjusted EBITDA of $13.9 million, up 73% year-over-year. The company also reported positive free cash flow of $1.5 million and net income. Key drivers included strong performance from its German medical cannabis subsidiary, Remexian Pharma GmbH, which generated $31.6 million in revenue with 27% gross margins, and continued growth in its Canadian retail operations, evidenced by a 39% increase in Cabana Club memberships. High Tide also secured $40 million in credit facilities from Bank of Montreal to support growth.

High Tide Inc. has released its unaudited condensed interim consolidated financial statements for the three and six months ended April 30, 2026. The company reported significant revenue growth, with Q1 revenue reaching $179.3 million and six-month revenue at $357.6 million. Notably, High Tide swung to a net income of $0.02 million for the quarter, a substantial improvement from a net loss in the prior year, and reduced its six-month net loss to $0.33 million. The company's balance sheet shows total assets of $347.9 million and shareholders' equity of $101.9 million as of April 30, 2026.

High Tide Inc. announced it has secured credit approval for new senior secured credit facilities totaling C$40 million with Bank of Montreal. These facilities will replace the Company's existing senior credit facility, providing C$25 million as a revolving facility for working capital and acquisitions, and a C$15 million delayed draw term loan to refinance existing second-lien debentures. The CEO, Raj Grover, highlighted this as a defining moment, securing lower-cost capital for the company's next phase of growth. Closing is anticipated within approximately 30 days, pending customary conditions.